Alvogen
Tracked across 3 events · 25 articles · First seen Jan 29, 2026 · Last active Mar 31, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Alvogen has resolved all remaining patent disputes worldwide related to its biosimilar to Eylea, securing global rights to manufacture and supply the aflibercept biosimilar. This positions Alvogen for successful commercial launches in various markets.
Jan 29, 2026 · 8 articles
Regulatory
Alvogen's stock price fell significantly after the United States===Food and Drug Administration (FDA) issued a complete response letter for its Biologics License Application for AVT05. This event has led to a class action lawsuit against Alvogen for allegedly issuing misleading business information.
Jan 29, 2026 · 7 articles
Business
Alvogen announced it will release its fourth quarter and full year 2025 financial and operating results, which is a routine financial disclosure for a publicly traded company. This event provides transparency to investors regarding Alvogen's performance.
Mar 04, 2026 · 10 articles
Regeneron Pharmaceuticals
competitor
↔
Alvogen
Alvogen's biosimilar competes with Regeneron Pharmaceuticals' Eylea.
Advanz Pharma
commercial partner
↔
Alvogen
Advanz Pharma is a commercial partner for Alvogen's Eylea biosimilar in Europe.
Biogaran
commercial partner
↔
Alvogen
Biogaran is a commercial partner for Alvogen's Eylea biosimilar in France.
Fuji Pharma
commercial partner
↔
Alvogen
Fuji Pharma is a commercial partner for Alvogen's Eylea biosimilar in Japan.
Stada Arzneimittel
commercial partner
↔
Alvogen
Stada Arzneimittel is a commercial partner for Alvogen's Eylea biosimilar in Ger
NEWSDESK
Track Alvogen live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard